NASDAQ:MDWD - Mediwound Stock Price, Forecast & News

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Mediwound Ltd (NASDAQ:MDWD) released its quarterly earnings results on Thursday, November, 14th. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.12. The biopharmaceutical company earned $5.14 million during the quarter, compared to analysts' expectations of $2.67 million. Mediwound had a negative return on equity of 94.57% and a net margin of 69.50%. View Mediwound's Earnings History.

Mediwound is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Mediwound.

Mediwound will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

2 brokerages have issued 1-year price objectives for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they expect Mediwound's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 109.7% from the stock's current price. View Analyst Price Targets for Mediwound.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mediwound.

Headlines about MDWD stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mediwound earned a news impact score of 0.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Mediwound.

Some companies that are related to Mediwound include Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Sundial Growers (SNDL), Happiness Biotech Group (HAPP), Natural Alternatives International (NAII), Mannatech (MTEX), FitLife Brands (FTLF), True Drinks (TRUU), Cyanotech (CYAN), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE) and Beleave (BE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Wells Fargo & Co (WFC), Mastercard (MA), Caesarstone (CSTE), Chubb (CB), Nordic American Tanker (NAT), Novavax (NVAX), Braskem (BRKMY) and Gilead Sciences (GILD).

Mediwound's stock is owned by many different of retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (1.87%), Renaissance Technologies LLC (1.50%), Sargent Investment Group LLC (0.29%), Sargent Investment Group LLC (0.22%), Acadian Asset Management LLC (0.20%) and Oppenheimer & Co. Inc. (0.16%).

MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd. and Oppenheimer & Co. Inc..

MDWD stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sargent Investment Group LLC, Acadian Asset Management LLC, Raymond James & Associates, Sargent Investment Group LLC, Tower Research Capital LLC TRC and UBS Group AG.

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MDWD stock can currently be purchased for approximately $2.98.

Mediwound has a market capitalization of $80.99 million and generates $3.40 million in revenue each year. The biopharmaceutical company earns $-1,060,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Mediwound employs 73 workers across the globe.View Additional Information About Mediwound.

The official website for Mediwound is http://www.mediwound.com/.

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]